Hyperhomocysteinemia and acute phase proteins in various forms of ischemic heart disease

Abstract


Aim. To determine clinical significance of high concentrations of homocystein, C-reactive protein, fibrinogen in various forms of ischemic heart disease.
Material and methods. Enzyme immunoassay was made to measure serum concentrations of homocystein, C-reactive protein, fibrinogen in 60 patients with ischemic heart disease (IHD) in the form of stable effort angina (n = 20), painless myocardial ischemia (n = 19), unstable angina pectoris (n = 21) and 20 control patients free of IHD. Myocardial ischemia was confirmed at dobutamine stress echocardiography.
Results. Serum concentrations of homocysteine, C-reactive protein and fibrinogen were higher in patients with unstable angina than in the other examinees with IHD. A statictically significant correlation exists between homocysteine serum levels and acute phase proteins (C-reactive protein, fibrinogen) in patients with unstable angina. In the other groups it was absent.
Conclusion. Correlation between serum levels of homocysteine and acute phase proteins in patients with unstable angina suggests a direct participation of this amino acid in destabilization of atherosclerotic plaques and development of acute coronary syndromes.

References

  1. Mudd S. H., Skovby F., Levy H. L. et al. The natural history of homocystinuria due to cystathioine beta-syntase deficiency. Am. J. Hum. Genet. 1985; 37: 1-31.
  2. Nygard O., Nordehaud J. E., Refsum H. et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 1997; 337: 230-236.
  3. Verhoef P., Hennekens С. H., Malinow M. R. et al. A prospective study of plasma homocysteine and risk of ischemic stroke. Stroke 1994; 25: 1924-1930.
  4. Spieker L. E., Luscher T. F., Noll G. et al. Beyond traditional risk factors: homocysteine and atherosclerosis. Biochemistry, physiology and evidence from clinical trials. Heart Drug 2001; 1: 160-168.
  5. Woo K. S., Chook P., Lolin Y. I. et al. Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 2542-2544.
  6. Bellamy M. F., McDowell I. F., Ramsey M. W. et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 1998; 98: 1848-1852.
  7. Harpel P. C., Chang V. Т., Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc. Natl. Acad. Sci. USA 1992; 89: 10193-10197.
  8. Poddar R., Sivasumbramanian N., Robinson K., Jacobsen D. W. Homocysteine modulates the expression of a specific cytokine (monocyte chemoattractant protein-1) in human aortic endothelial cells. Circulation 1997; 96: 281-286.
  9. Ефимов В. С., Цакалоф А. К. Гомоцистеинемия в патогенезе тромбоваскулярной болезни и атеросклероза. Лаб. мед. 1999; 2: 44-48.
  10. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. Med. 1999; 340: 115-126.
  11. Насонов Е. Л. Иммунологические маркеры атеросклеро Тер. арх. 2002; 74 (5): 80-85.
  12. Нагорнев В. А., Назаров П. Г., Полевщиков В. А. и др. Ат рогенез и реакция "острой фазы" печени. Арх. пат. 195 6: 62-68.
  13. Kuller L. H, Tracy R. P., Shaten J., Meilahn E. N. Relation C-reactive protein and coronary heart disease in MRFIT nei ed case-control study. Am. J. Epidemiol. 1996; 144: 537-54
  14. Koenig W., Sund M., Frohlich M. et al. C-reactive protein, sensitive marker of inflammation, predicts future risk of con nary heart disease in initially healthy middle-aged men: resul from the MONICA (Monitoring Trends and Determinants Cardiovascular Disease) Augsburg Cohort Study; 1984-199 Circulation 1999; 99: 237-242.
  15. Pasceri V., Chang J., Willerson J. Т., Yeh E. T. Modulation i C-reactive protein protein-mediated monocyte chemoattrac ant protein-1 induction in human endothelial cells by ant atherosclerosis drugs. Circulation 2001; 103: 2531-2534.
  16. Ridker P. M., Rifai N., Pfeffer M. A. et al. Long-term effects с pravastatin on plasma concentration of C-reactive proteir Circulation 1999; 100: 230-235.
  17. Albert M. A., Danielson E., Rifai N., Ridker P. M. Effect of sta tin therapy on C-reactive protein levels: the pravastatin inflam mation/CRP evaluation (PRINCE): a randomized trial am cohort study. J. A. M. A. 2001; 286: 64-70.
  18. Покровская Е. В., Ваулин Н. А., Грацианский Н. А. и др Острый коронарный синдром без подъема сегмента ST н; ЭКГ: агрегация тромбоцитов и маркеры воспаления npi раннем применении аторвастатина и правастатина. Кар диология 2003; 1: 7-18.
  19. Yildirir A., Tokgozoglu S. L., Hainedaroglu I. et al. Extent o: coronary atherosclerosis and homocysteine affect endothelial markers. Angiology 2001; 52: 589-596.
  20. Tavares J. R., D'Almeida V., Diniz D. C. Analysis of plasma homocyteine levels in patients with unstable angina. Arq. Bras. Cardiol. 2002; 79: 161-172.
  21. Al-Obaidi M. K., Stubbs P. J., Collinson P. et al. Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes. J. Am. Coll. Cardiol. 2000; 36: 1217-1222.
  22. Omland Т., Samuelsson A., Hartford M. et al. Serum homocysteine concentration as an indicator of survival in patients with acute coronary syndromes. Arch, intern. Med. 2000; 160: 1834-1840.
  23. Stubbs P. J., Al-Obaidi M. K., Conroy R. M. et al. Effects of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation 2000; 102: 605-610.
  24. Al-Obaidi M. K., Stubbs P. J., Amersey R., Noble M. I. Acute and convalescent changes in plasma homocysteine concentrations in acute coronary syndromes. Heart 2001; 85: 380-384.

Statistics

Views

Abstract - 83

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Paramonov A.D., Moiseev S.V., Fomin V.V., Kopeleva M.V., Stankevich L.I., Martynov A.I., Mukhin N.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies